Special Issue

Advances in Mass Spectrometry Imaging-Based Cancer Research

Message from the Guest Editors

Discovering molecular signatures/pathways in cells, tissues, organs, and body fluids is of great relevance in cancer research as it may lead to a better understanding of tumor biology. The science of Omics such as genomics, proteomics, lipidomics, and metabolomics has provided new opportunities in the molecular analysis of cancer facilitating and improving diagnosis and treatment. (MS) technology have made the "-omic" revolution possible, facing a series of challenging tasks such as high sensitivity, specificity, throughput, robustness, flexibility, and quantification of complex biological samples. MS-based technologies offer an ever-increasing number of outstanding contributions in the field of cancer and have entered in many clinical settings. One of the recent areas of interest in MS is tissue imaging, i.e., MS imaging (MSI). This allows simultaneous visualization of the spatial distribution of hundreds of a broad variety of biomolecules ranging from peptides, to glycans, lipids, and even metabolites, known to play important roles in cancer, directly on tissue specimen.

Guest Editors

Dr. Rita Casadonte

Proteopath GmbH, Max-Planck-Str. 17, 54296 Trier, Germany

Dr. Kristina Schwamborn

Institute of Pathology, School of Medicine, Technical University of Munich, Trogerstr. 18, 81675 Munich, Germany

Dr. Mark Kriegsmann

Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany

Deadline for manuscript submissions

closed (28 February 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/111496

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

